Literature DB >> 29057276

Genetic Correlates of Spirituality/Religion and Depression: A Study in Offspring and Grandchildren at High and Low Familial Risk for Depression.

Micheline R Anderson1, Lisa Miller1, Priya Wickramaratne2,3,4, Connie Svob2,3, Zagaa Odgerel2,3, Ruixin Zhao2,3, Myrna M Weissman2,3,4.   

Abstract

RATIONALE: Possible genetic correlates of spirituality and depression have been identified in community samples. We investigate some of the previously identified candidates in a sample of families at both high and low-risk for depression.
METHOD: Offspring and grandchildren of individuals at high and low-risk for depression, participating in a multi-wave thirty-year longitudinal study, were assessed for seven SNPS drawn from four single gene candidates associated with systems implicated in both depression and spirituality: Serotonin (5-HT1B and 5-HT2A), Dopamine (DRD2), Oxytocin (OT) and Monoamine Vesicular Transporter (VMAT1).
RESULTS: Dopamine (DRD2) Serotonin (5-HT1B), their Transporter (VMAT1) and Oxytocin (OXTR) were positively associated with a high level of importance of spirituality or religion (S/R) in the group at low familial risk for depression. DRD2 minor allele was associated with both lifetime major depressive disorder (MDD) and spirituality in the low-risk group for depression. No SNPs were related to S/R in the group at high familial risk for depression. OXTR was associated with lifetime MDD in the full sample.
CONCLUSION: Genes for dopamine, serotonin, their vesicular transporter, and oxytocin may be associated with S/R in people at low familial risk for depression. Genes for dopamine may be associated both with S/R and increased risk for depression in people at low-risk for depression, suggesting a common pathway or physiology to mild to moderate depression. MDD is associated with oxytocin across risk groups. In the high-risk group, phenotypic expression of S/R may be suppressed. IMPLICATIONS: The shared association of DRD2 by S/R and depression, generally found to be inversely related, calls for further research on their common physiological pathways, and the phenotypic expression of these pathways based upon use and environment. Prevention for offspring at high familial risk for depression might include support for the development of child spirituality.

Entities:  

Year:  2017        PMID: 29057276      PMCID: PMC5646707          DOI: 10.1037/scp0000125

Source DB:  PubMed          Journal:  Spiritual Clin Pract (Wash D C )        ISSN: 2326-4500


  134 in total

Review 1.  The neural basis of the complex mental task of meditation: neurotransmitter and neurochemical considerations.

Authors:  A B Newberg; J Iversen
Journal:  Med Hypotheses       Date:  2003-08       Impact factor: 1.538

Review 2.  The addictive brain: all roads lead to dopamine.

Authors:  Kenneth Blum; Amanda L C Chen; John Giordano; Joan Borsten; Thomas J H Chen; Mary Hauser; Thomas Simpatico; John Femino; Eric R Braverman; Debmalya Barh
Journal:  J Psychoactive Drugs       Date:  2012 Apr-Jun

3.  Reduced ventral striatal/ventral pallidal serotonin1B receptor binding potential in major depressive disorder.

Authors:  James W Murrough; Shannan Henry; Jian Hu; Jean-Dominique Gallezot; Beata Planeta-Wilson; John F Neumaier; Alexander Neumeister
Journal:  Psychopharmacology (Berl)       Date:  2010-05-18       Impact factor: 4.530

Review 4.  Biochemical and genetic analyses of childhood attention deficit/hyperactivity disorder.

Authors:  Emrah Caylak
Journal:  Am J Med Genet B Neuropsychiatr Genet       Date:  2012-07-23       Impact factor: 3.568

5.  Oxytocin receptor gene polymorphism (rs2254298) interacts with familial risk for psychopathology to predict symptoms of depression and anxiety in adolescent girls.

Authors:  Renee J Thompson; Karen J Parker; Joachim F Hallmayer; Christian E Waugh; Ian H Gotlib
Journal:  Psychoneuroendocrinology       Date:  2010-08-14       Impact factor: 4.905

6.  Increased dopamine tone during meditation-induced change of consciousness.

Authors:  Troels W Kjaer; Camilla Bertelsen; Paola Piccini; David Brooks; Jørgen Alving; Hans C Lou
Journal:  Brain Res Cogn Brain Res       Date:  2002-04

Review 7.  Transmission and prevention of mood disorders among children of affectively ill parents: a review.

Authors:  William R Beardslee; Tracy R G Gladstone; Erin E O'Connor
Journal:  J Am Acad Child Adolesc Psychiatry       Date:  2011-09-15       Impact factor: 8.829

8.  Depression and openness to experience.

Authors:  M Wolfenstein; T J Trull
Journal:  J Pers Assess       Date:  1997-12

9.  The DRD2 gene 957C>T polymorphism is associated with posttraumatic stress disorder in war veterans.

Authors:  Joanne Voisey; Christopher D Swagell; Ian P Hughes; C Phillip Morris; Angela van Daal; Earnest P Noble; Burnett Kann; Karen A Heslop; Ross McD Young; Bruce R Lawford
Journal:  Depress Anxiety       Date:  2009       Impact factor: 6.505

Review 10.  Oxytocin and Vasopressin Receptor Gene Polymorphisms: Role in Social and Psychiatric Traits.

Authors:  Mauricio Aspé-Sánchez; Macarena Moreno; Maria Ignacia Rivera; Alejandra Rossi; John Ewer
Journal:  Front Neurosci       Date:  2016-01-28       Impact factor: 4.677

View more
  3 in total

1.  Multidimensional understanding of religiosity/spirituality: relationship to major depression and familial risk.

Authors:  Clayton H McClintock; Micheline Anderson; Connie Svob; Priya Wickramaratne; Richard Neugebauer; Lisa Miller; Myrna M Weissman
Journal:  Psychol Med       Date:  2018-11-13       Impact factor: 7.723

Review 2.  An Epigenetic Perspective on Lifestyle Medicine for Depression: Implications for Primary Care Practice.

Authors:  Jenny Sunghyun Lee; Paresh Atu Jaini; Frank Papa
Journal:  Am J Lifestyle Med       Date:  2020-09-10

3.  Understanding self-reported importance of religion/spirituality in a North American sample of individuals at risk for familial depression: A principal component analysis.

Authors:  Connie Svob; Lidia Y X Wong; Marc J Gameroff; Priya J Wickramaratne; Myrna M Weissman; Jürgen Kayser
Journal:  PLoS One       Date:  2019-10-18       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.